Island Pharmaceuticals Ltd (ASX:ILA) has dosed the third cohort of its single ascending dose study on ISLA-101, a drug candidate being repurposed for the treatment and prevention of dengue fever and other mosquito-borne diseases.
The third cohort was dosed under fasted conditions following confirmation from the data safety review committee that ISLA-101 was deemed safe and tolerable for the 16 subjects dosed across cohorts 1 and 2.
Pending review of cohort 3 results, the cohort who received the highest safe dose will return to be treated under fed conditions for final dosing.
Moving forward, Island remains on track to report trial data in early 2024.
Moving towards completion
Island CEO Dr David Foster said: “We are very pleased with how this study is progressing and thank all those volunteers participating in it.
"With the dose now administered to the third cohort, we are moving swiftly toward the completion of dosing for this study.
Based on our current progress, we remain on track to read out data in early 2024.”
About ISLA-101
ISLA-101 is a well-known drug candidate, being repurposed for the prevention and treatment of dengue fever and other mosquito (or vector) borne diseases.
The single ascending dose study is designed to ensure that administered doses can safely achieve blood concentrations of ISLA-101 that are predicted to be effective against the dengue virus.
The study is paving the way for Island’s planned Phase 2a PEACH clinical trial.